Current Report Filing (8-k)
January 09 2018 - 7:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of Earliest Event Reported):
January 9, 2018
Ekso
Bionics Holdings, Inc.
(Exact Name of Registrant
as specified in its charter)
Nevada
|
|
001-37854
|
|
99-0367049
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification
No.)
|
1414 Harbour Way
South, Suite 1201
Richmond, California
94804
(Address of principal
executive offices, including zip code)
(510) 984-1761
(Registrant’s
telephone number, including area code)
Not Applicable
(Registrant’s
former name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
|
¨
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 2.02
|
Results
of Operations and Financial Condition
|
On
January 9, 2018, Ekso Bionics Holdings, Inc. (the “Company”) reported preliminary financial results for the quarter
and year ended December 31, 2017. The full text of the press release announcing such results is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
The
information contained in this report, including the information contained in Exhibit 99.1, is being furnished and shall not be
deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or incorporated
by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation
language in such filing.
|
Item 9.01
|
Financial
Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
|
Maximilian Scheder-Bieschin
|
|
Name:
|
Maximilian Scheder-Bieschin
|
|
Title:
|
Chief Financial Officer
|
Dated: January
9, 2018
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024